Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial
Recruiting
Phase 2
Interventional Study
Cervical Cancer
Immunochemotherapy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 70
- Sex
- Female
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 59 (estimated)
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Patients with cervical cancer staged FIGO2018 IIIC1p or IIIC2p after radical surgery;
2. Positive PD-L1 expression;
3. ECOG score ≤1
Exclusion Criteria:
1. Positive parametrium or surgical margin;
2. Incomplete radical surgery;
3. Residual target lesions;
4. Active autoimmu…
Contacts
No contact information available.